Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical screening strategies were determined in baseline screening, first year re-call, and subsequent follow-up. (B) The cases of CIN3+ detected by three current cervical screening strategies were calculated in baseline screening, first year re-call, and subsequent follow-up. (C) For baseline screening, according to the different cervical screening strategies, the number of cytologic assays, HPV assays, and colposcopies that should be performed as well as analysis of CIN2+ cases that could be detected. (D) The three cervical screening strategies used for CIN3+ detection, with application of cytology assay, HPV assay, and colposcopy shown.
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; TCT, thinprep cytologic test.